HCMAMEDIUM SIGNALFINANCIAL10-Q

HCMA, a blank check company incorporated in April 2025, has progressed through its initial public offering phase and is now operating with cash reserves while seeking a business combination target.

As a newly formed SPAC, HCMA has transitioned from pre-IPO operations to post-IPO status, establishing the typical redemption mechanisms for public shareholders and building the operational infrastructure needed to identify and execute an initial business combination. The company's current liquidity position provides the foundation for evaluating potential merger targets while managing ongoing formation and administrative costs.

Comparing 2025-11-14 vs 2025-09-15View on EDGAR →
FINANCIAL ANALYSIS

The company's balance sheet reflects typical early-stage SPAC dynamics, with current assets declining modestly to $964K while current liabilities grew meaningfully to $902K, indicating increased operational activity following the IPO. Cash and equivalents increased substantially to $84K, though this represents a relatively small absolute amount for SPAC operations. The overall financial picture shows a company in the early phases of its business combination search period, with adequate near-term liquidity but the typical cash burn pattern of formation-stage SPACs.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+59.7%
$52K$84K

Cash position surged 59.7% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
+35.7%
$665K$902K

Current liabilities surged 35.7% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
-11.5%
$1.1M$964K

Current assets declined 11.5% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2025-11-14
PRIOR — 2025-09-15
ADDED
See definitions of large accelerated filer , accelerated filer , smaller reporting company , and emerging growth company in Rule 12b-2 of the Exchange Act.
(the Company ) is a blank check company incorporated as a Cayman Islands exempted corporation on April 15, 2025 .
As of September 30, 2025, the Company has not commenced any operations.
The Company will provide the Company s public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a general meeting called to approve the initial Business Combination or (ii) without a shareholder vote by means of a tender offer.
Liquidity and Capital Resources The Company s liquidity needs up to September 30, 2025 had been satisfied through the loan under an unsecured promissory note.
At September 30, 2025, the Company had cash of $ 1,144,833 and working capital of $ 1,129,082 .
As of August 4, 2025, no such Working Capital Loans were outstanding.
Management has determined that the Company has sufficient funds to finance the working capital needs of the Company within one year from the date of issuance of the financial statement.
Use of Estimates The preparation of the unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements.
Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
REMOVED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Interim Financial Statements 1 Condensed Balance Sheet as of June 30, 2025 (Unaudited) 1 Condensed Statement of Operations for the period from April 15, 2025 (Inception) Through June 30, 2025 (Unaudited) 2 Condensed Statement of Changes in Shareholder s Deficit for the period from April 15, 2025 (Inception) Through June 30, 2025 (Unaudited) 3 Condensed Statement of Cash Flows for the period from April 15, 2025 (Inception) Through June 30, 2025 (Unaudited) 4 Notes to Condensed Financial Statements (Unaudited) 5 Item 2.
CONDENSED STATEMENT OF OPERATIONS FOR THE PERIOD FROM APRIL 15, 2025 (INCEPTION) THROUGH JUNE 30, 2025 (UNAUDITED) Formation, general and administrative costs $ 47,545 Loss from Operations ( 47,545 ) Net loss $ ( 47,545 ) Basic and diluted weighted average Class B ordinary shares outstanding (1) 7,333,333 Basic and diluted net loss per Class B ordinary share $ ( 0.01 ) (1) Excludes an aggregate of up to 1,100,000 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full (Note 5).
(the Company ) is a blank check company incorporated as a Cayman Islands exempted corporation on April 15, 2025.
As of June 30, 2025, the Company has not commenced any operations.
The ordinary shares subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) Topic 480, Distinguishing Liabilities from Equity.
At June 30, 2025, the Company had no cash and working capital deficit of $ 420,227 .
As of June 30, 2025, no such Working Capital Loans were outstanding.
Management has determined that upon the consummation of the Initial Public Offering and the sale of the Private Placement Warrants, the Company has sufficient funds to finance the working capital needs of the Company within one year from the date of issuance of the unaudited condensed financial statements (see Note 9).
At August 4, 2025, the Initial Public Offering closing date, the Company had $ 1,306,160 cash and working capital of $ 1,269,265 .
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →